Market Place
Sourcing Support
Prime Medicine Reveals 2025 Financials And Business Updates
03 Mar 2026 //
GLOBENEWSWIRE
Prime Medicine To Participate In Upcoming Investor Conferences
25 Feb 2026 //
GLOBENEWSWIRE
Prime Medicine To Present At J.P. Morgan Healthcare Conference
07 Jan 2026 //
GLOBENEWSWIRE
Prime Med Publishes PM359 in Chronic Granulomatous Disease Data
07 Dec 2025 //
GLOBENEWSWIRE
Prime Medicine To Present At Evercore Healthcare Conference
25 Nov 2025 //
GLOBENEWSWIRE
Prime Medicine To Showcase At Jefferies Healthcare Conference
11 Nov 2025 //
GLOBENEWSWIRE
Prime Medicine Reveals Q3 2025 Financials & Business Updates
07 Nov 2025 //
GLOBENEWSWIRE
Prime Medicine Names Matthew Hawryluk, Ph.D. as CBO
03 Nov 2025 //
GLOBENEWSWIRE
Prime Medicine Hosts KOL Event on Wilson’s Disease Strategy
30 Oct 2025 //
GLOBENEWSWIRE
Prime Medicine To Participate In Upcoming Investor Conferences
07 Oct 2025 //
GLOBENEWSWIRE
Prime Medicine to Participate in Upcoming Investor Conferences
26 Aug 2025 //
GLOBENEWSWIRE
Prime Medicine Reports Q2 2025 Financials and Updates
07 Aug 2025 //
GLOBENEWSWIRE
Prime Medicine closes public offering, underwriters fully
01 Aug 2025 //
GLOBENEWSWIRE
Prime Medicine Proposes Public Common Stock Offering
30 Jul 2025 //
GLOBENEWSWIRE
Prime Medicine Reveals Public Offering Pricing
30 Jul 2025 //
GLOBENEWSWIRE
Prime Gets $24M from CF Foundation for Treatment Push
16 Jul 2025 //
GLOBENEWSWIRE
Prime Medicine Restructures to Focus on Genetic Liver Diseases
19 May 2025 //
GLOBENEWSWIRE
Prime Medicine Reports Q1 2025 Results and Business Updates
08 May 2025 //
GLOBENEWSWIRE
Prime Medicine Reports FY 2024 Results & Business Updates
28 Feb 2025 //
GLOBENEWSWIRE
Prime Medicine to Present at TD Cowen Health Care Conference
24 Feb 2025 //
GLOBENEWSWIRE
Prime Medicine to Present at 43rd Annual J.P. Morgan Conference
07 Jan 2025 //
GLOBENEWSWIRE
Prime Medicine Presents Wilson’s Disease Data At ESGCT Congress
24 Oct 2024 //
GLOBENEWSWIRE
Prime Medicine Highlights Preclinical Data In Wilson’s Disease
15 Oct 2024 //
GLOBENEWSWIRE
BMS pays Prime $110M to form T-cell therapy pact
01 Oct 2024 //
PRESS RELEASE
Prime Medicine Collab with BMS To Develop Edited T-Cell Therapies
30 Sep 2024 //
GLOBENEWSWIRE
Prime Medicine to Participate in Upcoming Investor Conferences
28 Aug 2024 //
GLOBENEWSWIRE
Prime Medicine Reports Q2 2024 Results And Provides Business Updates
08 Aug 2024 //
GLOBENEWSWIRE
Prime Medicine CGD Gene Editing Data For PM359
08 May 2024 //
GLOBENEWSWIRE
Prime Medicine partners with Versant-backed biotech
22 Jun 2023 //
ENDPTS
Prime Medicine considers focus on autoimmune diseases for CAR-T, CEO says
15 Jun 2023 //
ENDPTS
